20249-17-6

Basic information

• Product Name: 3-Hydroxycyclobutanecarbonitrile
• Synonyms: 3-Hydroxycyclobutanecarbonitrile;3-hydroxycyclobutane-1-carbonitrile
• CAS NO: 20249-17-6
• Molecular Formula: C₅H₇NO
• Molecular Weight: 97.11518
• Mol File: 20249-17-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 70-71 °C(Press: 0.33 Torr)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• PKA: 14.28±0.40(Predicted)
• CAS DataBase Reference: 3-Hydroxycyclobutanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxycyclobutanecarbonitrile(20249-17-6)
• EPA Substance Registry System: 3-Hydroxycyclobutanecarbonitrile(20249-17-6)

Safety Data

• RIDADR: UN2810
• Hazardous Substances Data: 20249-17-6(Hazardous Substances Data)

Usage

Uses

3-hydroxycyclobutane-1-carbonitrile is a useful research chemical.

Upstream product

• 20249-16-5 3-oxo-cyclobutanecarbonitrile 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 

Downstream Products

• 1544741-03-8 3-(3,5-dimethylphenoxy)cyclobutanecarbonitrile 
• 938064-64-3 3-(4-methoxy-benzyloxy)-cyclobutanecarbonitrile 
• 167081-42-7 3-(aminomethyl)cyclobutanol 

Relevant articles and documents

AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions

Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).